- Home
- KROS vs STK Comparison
KROS vs STK Comparison
Compare KROS & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- STK
- Stock Information
- Founded
- KROS 2015
- STK 2009
- Country
- KROS United States
- STK United States
- Employees
- KROS N/A
- STK N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- STK Investment Managers
- Sector
- KROS Health Care
- STK Finance
- Exchange
- KROS Nasdaq
- STK Nasdaq
- Market Cap
- KROS 565.0M
- STK 511.3M
- IPO Year
- KROS 2020
- STK N/A
- Fundamental
- Price
- KROS $13.73
- STK $31.18
- Analyst Decision
- KROS Buy
- STK
- Analyst Count
- KROS 14
- STK 0
- Target Price
- KROS $20.56
- STK N/A
- AVG Volume (30 Days)
- KROS 442.6K
- STK 38.2K
- Earning Date
- KROS 08-06-2025
- STK 01-01-0001
- Dividend Yield
- KROS N/A
- STK 6.60%
- EPS Growth
- KROS N/A
- STK N/A
- EPS
- KROS 0.47
- STK N/A
- Revenue
- KROS $232,844,000.00
- STK N/A
- Revenue This Year
- KROS $5,390.70
- STK N/A
- Revenue Next Year
- KROS N/A
- STK N/A
- P/E Ratio
- KROS $29.50
- STK N/A
- Revenue Growth
- KROS 85820.30
- STK N/A
- 52 Week Low
- KROS $9.12
- STK $24.95
- 52 Week High
- KROS $72.37
- STK $34.31
- Technical
- Relative Strength Index (RSI)
- KROS 43.50
- STK 61.57
- Support Level
- KROS $13.13
- STK $30.57
- Resistance Level
- KROS $14.75
- STK $31.35
- Average True Range (ATR)
- KROS 0.49
- STK 0.34
- MACD
- KROS -0.09
- STK -0.03
- Stochastic Oscillator
- KROS 34.96
- STK 77.97
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.